Get the Stockscreener App
8.95
2.05%
0.18
After Hours:
8.95
Kyverna Therapeutics Inc stock is traded at $8.95, with a volume of 561.08K.
It is up +2.05% in the last 24 hours and up +23.28% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$8.77
Open:
$8.92
24h Volume:
561.08K
Relative Volume:
0.40
Market Cap:
$533.48M
Revenue:
-
Net Income/Loss:
$-110.66M
P/E Ratio:
-2.8905
EPS:
-3.0963
Net Cash Flow:
$-97.76M
1W Performance:
+10.49%
1M Performance:
+23.28%
6M Performance:
+128.32%
1Y Performance:
+258.00%
1-Day Range:
$8.72
$9.25
1-Week Range:
$8.00
$9.70
52-Week Range:
$1.78
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.95 | 522.75M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
KYTX: Pivotal miv-cel data in SPS shows disease reversal, with BLA filing and launch planned this year - TradingView
How Kyverna Therapeutics Inc. stock compares to growth peersWeekly Stock Report & Long Hold Capital Preservation Tips - Naître et grandir
Portfolio Recap: Is Kyverna Therapeutics Inc stock trending bullishBreakout Watch & Safe Entry Zone Tips - baoquankhu1.vn
Kyverna to present stiff person syndrome trial data at AAN meeting - Investing.com Australia
Kyverna secures up to $150M loan facility from Oxford Finance - MSN
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - Sahm
Kyverna Therapeutics Announces Presentations on Miv-cel Research at AAN Annual Meeting 2026 - Quiver Quantitative
New cell therapy data in stiff person syndrome set for AAN 2026 - Stock Titan
Aug Fed Impact: What is the Moat Score of Kyverna Therapeutics IncWeekly Profit Recap & Verified Short-Term Trading Plans - baoquankhu1.vn
Director Andrew Craig Miller files initial Form 3 at Kyverna (KYTX) - Stock Titan
Kyverna Therapeutics (KYTX) director awarded options and RSUs in equity grant - Stock Titan
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Biotech Kyverna lines up March talks at Leerink, Jefferies events - Stock Titan
Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha
P5002025 Year in Review & Long-Term Safe Return Strategies - mfd.ru
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Director at Kyverna Therapeutics (KYTX) granted options and RSUs - Stock Titan
Kyverna Therapeutics (KYTX) director Emany Sravan Kumar files Form 3 - Stock Titan
Is Kyverna Therapeutics Inc. undervalued by DCF analysisMarket Volume Report & AI Powered Trade Plan Recommendations - mfd.ru
Intellia’s New Cell Therapy Alliances Add Optionality To Growth Story - Sahm
Kyverna adds two directors as board prepares for commercial stage By Investing.com - Investing.com Canada
Beam Therapeutics Inc. announced that it expects to receive $500 million in funding - marketscreener.com
Kyverna Therapeutics Strengthens Board With New Director Appointments - TipRanks
Kyverna Therapeutics appoints biotech leaders Sravan Emany and Andrew Miller to board of directors - marketscreener.com
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors - Bitget
Biotech leaders join Kyverna Therapeutics (KYTX) board as Spiegelman exits - Stock Titan
KYTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
KYTXKyverna Therapeutics Latest Stock News & Market Updates - Stock Titan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bain Capital Life Sciences discloses 5.4% Kyverna (KYTX) ownership stake - Stock Titan
Rubin-led Northpond funds show 6.1% Kyverna (KYTX) stake in 13G/A - Stock Titan
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year - Yahoo Finance
What’s Kyverna Therapeutics Inc.’s historical returnOil Prices & Safe Investment Capital Preservation Plans - mfd.ru
Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat
What is the Moat Score of Kyverna Therapeutics IncMarket Risk Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
Does Kyverna Therapeutics Inc. outperform in volatile marketsJuly 2025 EndofMonth & Verified Entry Point Signals - mfd.ru
Profit Review: Can Kyverna Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Value Report & Reliable Volume Spike Trade Alerts - mfd.ru
Kyverna Therapeutics (KYTX) CTO Mayobanex Pujols reports no share ownership on Form 3 - Stock Titan
Stock Recap: Is AIRT a defensive stockWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
Myasthenia Gravis Market Forecast Indicates 10.4% CAGR Growth by 2034, Reports DelveInsight - Barchart.com
Aug Reactions: Can Kyverna Therapeutics Inc weather a recessionQuarterly Market Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Aug PostEarnings: Does Koninklijke Philips NV Depositary Receipt outperform in volatile marketsQuarterly Trade Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Income Plays: Can Kyverna Therapeutics Inc maintain sales growthJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Aug Momentum: How Kyverna Therapeutics Inc. stock performs after earningsEarnings Miss & Short-Term Trading Opportunity Alerts - mfd.ru
Kyverna Therapeutics appoints Mayo Pujols as chief technology officer By Investing.com - Investing.com Nigeria
Kyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing - TipRanks
Kyverna Therapeutics appoints Mayo Pujols as chief technology officer - Investing.com
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer - Quiver Quantitative
Fund Flows: Is Kyverna Therapeutics Inc stock trending bullishEarnings Trend Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Valuation Update: Is Scully Royalty Ltd on track to beat earningsGold Moves & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Street Watch: Can Kyverna Therapeutics Inc weather a recessionSell Signal & Safe Entry Zone Identification - baoquankhu1.vn
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):